OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Neurology Neurosurgery and Psychiatry is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
35 Processing speed (PS) improvement in alcohol related brain damage (ARBD)	125
Navigating the presymptomatic frontier in genetic ALS and FTD	99
086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes	93
164 Progressive multifocal leukoencephalopathy (PML) following autologous periph- eral blood stem cell transplantation for multiple myeloma	86
West is best – a strongman with numb feet	81
099 Safety and effectiveness of dimethyl fumarate in multiple sclerosis patients treated over 5 years	80
094 Measuring neutralising antibodies (NAbs) to interferon-beta (IFNB) for multiple sclerosis (MS): a neglected practice?	80
005 Infusion associated reactions in ocrelizumab-treated multiple sclerosis patients	78
122 Neurological manifestations of haemophagocytic lymphohistiocytosis	78
102 The cost of misdiagnosis in POEMS syndrome	73
White matter hyperintensities and brain microbleeds in ataxia-telangiectasia: the Cambridge cohort	69
001 Machine learning accurately determines the population prevalence of Alzheimer’s disease based on microbiome profile	67
143 Catastrophising cognitions in patients with psychogenic non-epileptic seizures compared to patients with epilepsy	66
010 Safety and efficacy of long-term dimethyl fumarate treatment	64
201 Management of an unusual presentation of spontaneous intracranial hypotension (SIH)	64
184 Right data, right care	63
238 Cogniton and mood disorder in cervical dystonia	61
12 A pilot investigation of interoceptive accuracy, awareness, and sensibility in functional neurological disorder	60
L-arginine and mitochondrial encephalomyopathy, lactic acidosis and stroke- like episodes (MELAS): a systematic review	60
Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis	58
102 Levodopa and melanoma what do clinicians think?	57
175 A case series of anti-HMGCR immune mediated necrotizing myopathy: the West Midlands data	57
091 The East London Parkinson’s disease project – engaging a diverse population in research	57
059 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?	54
117 Who is the culprit – the virus or the anti-virus?	51

Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease	50
226 Reduced synaptic density in progressive supranuclear palsy and corticobasal syndrome, revealed by [11C]UCB-J PET	50
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis	49
Improved naming in patients with Broca’s aphasia with tDCS	48
101 Motor and non-motor features of prodromal PD	47
091 CIDP mimic in a patient with HIV; An unusual presentation of POEMS syndrome	47
114 Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease	46
003 Neuroanatomical signatures of genetic risk for Alzheimer’s disease in healthy adults	46
High frequency ofHTRA1ANDABCC6mutations in Japanese patients with adult-onset cerebral small vessel disease	44
Sodium valproate is associated with cortical thinning of disease-specific areas in juvenile myoclonic epilepsy	44
Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts	43
Neural (re)organisation of language and memory: implications for neuroplasticity and cognition	43
Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning	43
Early treatment of type II SMA slows rate of progression of scoliosis	41
Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis	41
Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study	41